| 产品描述： | Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7 |
| 靶点： |
HIV Protease; TLR |
| 体外研究： |
Administration of 6-60 μM Gardiquimod obviously inhibits HIV-1 reverse transcriptase cDNA synthesis |
| 体内研究： |
Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) in combination with Dendritic cells (DCs) enhance the anti-tumor effects of NK cells |
| 参考文献： |
1. Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18. 2. Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306. |
| 溶解性： |
Soluble in DMSO、DMF |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.191 ml |
15.954 ml |
31.908 ml |
| 5 mM |
0.638 ml |
3.191 ml |
6.382 ml |
| 10 mM |
0.319 ml |
1.595 ml |
3.191 ml |
| 50 mM |
0.064 ml |
0.319 ml |
0.638 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京